AmeriCann (OTCQB: ACAN), a cannabis company that develops state-of-the-art cultivation, product manufacturing and distribution facilities, today released financial and operational results for its fiscal quarter ending March 31, 2022. According to the update, the company achieved a significant increase in year-over-year quarterly revenue, culminating in positive net income for the quarter. Revenue from operations increased over 52% for the quarter ended March 2022 relative to the same quarter in 2021, an increase of $230,021. AmeriCann set an all-time monthly record in revenue for April 2022 and attributes the increase in financial performance to greater revenue received from products produced and manufactured at Building 1, the company’s initial building at its Massachusetts Cannabis Center development in Freetown, Massachusetts. “The success we have achieved with Building 1 is a testament to the quality of consistent products being produced for patients and consumers,” said AmeriCann CEO and President Tim Keogh. “The increased revenue, margins and profits we have achieved validates our vision for the Massachusetts Cannabis Center and our expansion plans.”
To view the full press release, visit https://ibn.fm/87j08
About AmeriCann
AmeriCann develops and leases cannabis cultivation, processing and product manufacturing facilities. AmeriCann uses greenhouse technology, which is superior to the current industry standard of growing cannabis in warehouse facilities under artificial lights. According to industry experts, by capturing natural sunlight, greenhouses use 25% fewer lights, and utility bills are up to 75% less than in typical warehouse cultivation facilities. As such, AmeriCann’s Cannopy System enables cannabis to be produced with a greatly reduced carbon footprint, making the final product less expensive. Additionally, greenhouse construction costs are nearly half of warehouse construction costs. AmeriCann is also designing GMP-Certified cannabis extraction and product manufacturing infrastructure. AmeriCann has secured licenses to produce cannabis-infused products including beverages, edibles, topicals and concentrates. AmeriCann plans to operate a marijuana product manufacturing business at the Massachusetts Cannabis Center. For more information about the company, visit www.AmeriCann.co.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.